Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
RBC Capital to hold a virtual conference » 04:55
05/20/20
05/20
04:55
05/20/20
04:55
ADUS

Addus HomeCare

$89.04 /

-0.89 (-0.99%)

, HOOK

Hookipa Pharma

$9.27 /

-0.88 (-8.67%)

, KPTI

Karyopharm

$17.68 /

-0.97 (-5.20%)

, UHS

Universal Health

$101.01 /

+0.55 (+0.55%)

, ENTA

Enanta

$54.33 /

-3.25 (-5.64%)

, REGN

Regeneron

$557.61 /

-1.76 (-0.31%)

, ARAV

Aravive

$12.27 /

-0.31 (-2.46%)

, IMGN

ImmunoGen

$4.62 /

-0.14 (-2.94%)

, HCA

HCA Healthcare

$103.94 /

-1.63 (-1.54%)

, PFE

Pfizer

$37.68 /

-0.4 (-1.05%)

, BCEL

Atreca

$18.06 /

-0.69 (-3.68%)

, JAZZ

Jazz Pharmaceuticals

$113.07 /

-3.23 (-2.78%)

, OVID

Ovid Therapeutics

$4.46 /

+0.29 (+6.95%)

, ACAD

Acadia

$51.02 /

-1.05 (-2.02%)

, BMRN

BioMarin

$93.88 /

-1.46 (-1.53%)

, EHTH

eHealth

$124.65 /

-2.38 (-1.87%)

, EXEL

Exelixis

$24.87 /

-0.79 (-3.08%)

, INO

Inovio

$14.56 /

+0.41 (+2.90%)

, SPRT

Support.com

$1.25 /

-0.01 (-0.79%)

, CYH

Community Health

$3.11 /

-0.05 (-1.58%)

, INCY

Incyte

$94.92 /

-1.58 (-1.64%)

, AGIO

Agios Pharmaceuticals

$47.89 /

-0.93 (-1.90%)

, EGRX

Eagle Pharmaceuticals

$53.24 /

-1.26 (-2.31%)

, IGMS

IGM Biosciences

$52.75 /

-2.66 (-4.80%)

, AIMT

Aimmune

$16.55 /

-0.92 (-5.27%)

, VRCA

Verrica Pharmaceuticals

$10.11 /

-0.62 (-5.78%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference will be held on May 19-20.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

SPRT Support.com
$1.25 /

-0.01 (-0.79%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

ENTA Enanta
$54.33 /

-3.25 (-5.64%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

BCEL Atreca
$18.06 /

-0.69 (-3.68%)

ARAV Aravive
$12.27 /

-0.31 (-2.46%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

03/20/20 RBC Capital
RBC says Addus HomeCare selloff unwarranted as lockdowns don't apply
12/10/19 Oppenheimer
Addus HomeCare price target raised to $107 from $96 at Oppenheimer
11/21/19 RBC Capital
Addus HomeCare price target raised to $109 from $100 at RBC Capital
11/06/19 RBC Capital
Addus HomeCare price target raised to $100 from $90 at RBC Capital
HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
UHS Universal Health
$101.01 /

+0.55 (+0.55%)

04/29/20 Deutsche Bank
Universal Health price target lowered to $135 from $165 at Deutsche Bank
04/28/20 Citi
Universal Health price target lowered to $128 from $157 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
ENTA Enanta
$54.33 /

-3.25 (-5.64%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
REGN Regeneron
$557.61 /

-1.76 (-0.31%)

05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
ARAV Aravive
$12.27 /

-0.31 (-2.46%)

04/30/20 Piper Sandler
Aravive partnering with WuXi to develop CCN2 antibodies, says Piper Sandler
03/27/20 H.C. Wainwright
Aravive price target lowered to $15 from $25 at H.C. Wainwright
02/18/20 Piper Sandler
IDMC recommends dose escalation in Aravive trial, says Piper Sandler
01/13/20 Piper Sandler
Piper Sandler reiterated Overweight on Aravive after AVB-500 expansion
IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

04/27/20 UBS
HCA Healthcare price target lowered to $138 from $183 at UBS
04/22/20 SunTrust
HCA Healthcare price target lowered to $140 from $160 at SunTrust
04/22/20 Deutsche Bank
HCA Healthcare price target lowered to $132 from $165 at Deutsche Bank
04/22/20 Oppenheimer
HCA Healthcare price target lowered to $135 from $160 at Oppenheimer
PFE Pfizer
$37.68 /

-0.4 (-1.05%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
05/15/20 William Blair
Sarepta maintains leadership position after Pfizer data, says William Blair
BCEL Atreca
$18.06 /

-0.69 (-3.68%)

04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/15/20 Baird
Atreca initiated with an Outperform at Baird
JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
05/06/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $113 from $127 at Piper Sandler
OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
09/23/19 Piper Sandler
Piper says Ovid shares reflect little value for 'exciting' soticlestat program
ACAD Acadia
$51.02 /

-1.05 (-2.02%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
EHTH eHealth
$124.65 /

-2.38 (-1.87%)

05/14/20 Raymond James
Raymond James says eHealth accounting more conservative than some peers
05/14/20 Craig-Hallum
CMS' SEP to be like new Easter season for eHealth, says Craig-Hallum
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
04/24/20 SunTrust
eHealth's path to over 50% growth has been made easier, says SunTrust
EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
INO Inovio
$14.56 /

+0.41 (+2.90%)

04/30/20 Roth Capital
Inovio downgraded to Neutral from Buy at Roth Capital
04/29/20 Cantor Fitzgerald
Inovio price target raised to $17 from $13 at Cantor Fitzgerald
04/29/20 H.C. Wainwright
Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright
04/29/20 Stifel
Stifel more than doubles Inovio target to $19, sees favorable setup
SPRT Support.com
$1.25 /

-0.01 (-0.79%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

02/24/20 RBC Capital
Community Health price target raised to $8 from $4 at RBC Capital
02/20/20 Raymond James
Community Health upgraded at Raymond James as near-term pressures limited
02/20/20 Raymond James
Community Health upgraded to Market Perform from Underperform at Raymond James
INCY Incyte
$94.92 /

-1.58 (-1.64%)

05/19/20 Cantor Fitzgerald
Incyte price target raised to $100 from $83 at Cantor Fitzgerald
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Piper Sandler
IGM Biosciences price target raised to $81 from $53 at Piper Sandler
04/22/20 Wedbush
Wedbush bullish on IGM Biosciences, initiates with an Outperform
AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
03/23/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
11/27/19 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $23 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

ENTA Enanta
$54.33 /

-3.25 (-5.64%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

BCEL Atreca
$18.06 /

-0.69 (-3.68%)

ARAV Aravive
$12.27 /

-0.31 (-2.46%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

SPRT Support.com
$1.25 /

-0.01 (-0.79%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

Conference/Events
RBC Capital to hold a virtual conference » 08:45
05/19/20
05/19
08:45
05/19/20
08:45
ADUS

Addus HomeCare

$89.93 /

+5.99 (+7.14%)

, HOOK

Hookipa Pharma

$10.15 /

+0.78 (+8.32%)

, KPTI

Karyopharm

$18.65 /

-0.4 (-2.10%)

, UHS

Universal Health

$100.46 /

+7.86 (+8.49%)

, ENTA

Enanta

$57.58 /

+2.25 (+4.07%)

, REGN

Regeneron

$559.37 /

-16.71 (-2.90%)

, ARAV

Aravive

$12.58 /

+0.11 (+0.88%)

, IMGN

ImmunoGen

$4.76 /

+0.33 (+7.45%)

, HCA

HCA Healthcare

$105.57 /

+6.83 (+6.92%)

, PFE

Pfizer

$38.08 /

+0.31 (+0.82%)

, BCEL

Atreca

$18.75 /

-0.44 (-2.29%)

, JAZZ

Jazz Pharmaceuticals

$116.30 /

+4.79 (+4.30%)

, OVID

Ovid Therapeutics

$4.17 /

+0.09 (+2.21%)

, ACAD

Acadia

$52.07 /

+1.23 (+2.42%)

, BMRN

BioMarin

$95.34 /

+1.595 (+1.70%)

, EHTH

eHealth

$127.03 /

+9.13 (+7.74%)

, EXEL

Exelixis

$25.66 /

-0.07 (-0.27%)

, INO

Inovio

$14.15 /

+0.73 (+5.44%)

, SPRT

Support.com

$1.26 /

+0.06 (+5.00%)

, CYH

Community Health

$3.16 /

+0.435 (+15.99%)

, INCY

Incyte

$96.50 /

+0.37 (+0.38%)

, AGIO

Agios Pharmaceuticals

$48.82 /

+2.38 (+5.12%)

, EGRX

Eagle Pharmaceuticals

$54.50 /

+1.74 (+3.30%)

, IGMS

IGM Biosciences

$55.41 /

-3.59 (-6.08%)

, AIMT

Aimmune

$17.47 /

+1.1 (+6.72%)

, VRCA

Verrica Pharmaceuticals

$10.73 /

+0.47 (+4.58%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference will be held on May 19-20.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

SPRT Support.com
$1.26 /

+0.06 (+5.00%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

ENTA Enanta
$57.58 /

+2.25 (+4.07%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

BCEL Atreca
$18.75 /

-0.44 (-2.29%)

ARAV Aravive
$12.58 /

+0.11 (+0.88%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

03/20/20 RBC Capital
RBC says Addus HomeCare selloff unwarranted as lockdowns don't apply
12/10/19 Oppenheimer
Addus HomeCare price target raised to $107 from $96 at Oppenheimer
11/21/19 RBC Capital
Addus HomeCare price target raised to $109 from $100 at RBC Capital
11/06/19 RBC Capital
Addus HomeCare price target raised to $100 from $90 at RBC Capital
HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
UHS Universal Health
$100.46 /

+7.86 (+8.49%)

04/29/20 Deutsche Bank
Universal Health price target lowered to $135 from $165 at Deutsche Bank
04/28/20 Citi
Universal Health price target lowered to $128 from $157 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
ENTA Enanta
$57.58 /

+2.25 (+4.07%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
REGN Regeneron
$559.37 /

-16.71 (-2.90%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
ARAV Aravive
$12.58 /

+0.11 (+0.88%)

04/30/20 Piper Sandler
Aravive partnering with WuXi to develop CCN2 antibodies, says Piper Sandler
03/27/20 H.C. Wainwright
Aravive price target lowered to $15 from $25 at H.C. Wainwright
02/18/20 Piper Sandler
IDMC recommends dose escalation in Aravive trial, says Piper Sandler
01/13/20 Piper Sandler
Piper Sandler reiterated Overweight on Aravive after AVB-500 expansion
IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

04/27/20 UBS
HCA Healthcare price target lowered to $138 from $183 at UBS
04/22/20 SunTrust
HCA Healthcare price target lowered to $140 from $160 at SunTrust
04/22/20 Deutsche Bank
HCA Healthcare price target lowered to $132 from $165 at Deutsche Bank
04/22/20 Oppenheimer
HCA Healthcare price target lowered to $135 from $160 at Oppenheimer
PFE Pfizer
$38.08 /

+0.31 (+0.82%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
05/15/20 William Blair
Sarepta maintains leadership position after Pfizer data, says William Blair
BCEL Atreca
$18.75 /

-0.44 (-2.29%)

04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/15/20 Baird
Atreca initiated with an Outperform at Baird
JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
05/06/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $113 from $127 at Piper Sandler
OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
09/23/19 Piper Sandler
Piper says Ovid shares reflect little value for 'exciting' soticlestat program
ACAD Acadia
$52.07 /

+1.23 (+2.42%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
EHTH eHealth
$127.03 /

+9.13 (+7.74%)

05/14/20 Raymond James
Raymond James says eHealth accounting more conservative than some peers
05/14/20 Craig-Hallum
CMS' SEP to be like new Easter season for eHealth, says Craig-Hallum
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
04/24/20 SunTrust
eHealth's path to over 50% growth has been made easier, says SunTrust
EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
INO Inovio
$14.15 /

+0.73 (+5.44%)

04/30/20 Roth Capital
Inovio downgraded to Neutral from Buy at Roth Capital
04/29/20 Cantor Fitzgerald
Inovio price target raised to $17 from $13 at Cantor Fitzgerald
04/29/20 H.C. Wainwright
Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright
04/29/20 Stifel
Stifel more than doubles Inovio target to $19, sees favorable setup
SPRT Support.com
$1.26 /

+0.06 (+5.00%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

02/24/20 RBC Capital
Community Health price target raised to $8 from $4 at RBC Capital
02/20/20 Raymond James
Community Health upgraded at Raymond James as near-term pressures limited
02/20/20 Raymond James
Community Health upgraded to Market Perform from Underperform at Raymond James
INCY Incyte
$96.50 /

+0.37 (+0.38%)

05/19/20 Cantor Fitzgerald
Incyte price target raised to $100 from $83 at Cantor Fitzgerald
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Piper Sandler
IGM Biosciences price target raised to $81 from $53 at Piper Sandler
04/22/20 Wedbush
Wedbush bullish on IGM Biosciences, initiates with an Outperform
AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
03/23/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
11/27/19 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $23 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

ENTA Enanta
$57.58 /

+2.25 (+4.07%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

BCEL Atreca
$18.75 /

-0.44 (-2.29%)

ARAV Aravive
$12.58 /

+0.11 (+0.88%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

SPRT Support.com
$1.26 /

+0.06 (+5.00%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

Hot Stocks
Agios announces publication of TIBSOVO Phase 3 data » 07:03
05/19/20
05/19
07:03
05/19/20
07:03
AGIO

Agios Pharmaceuticals

$48.82 /

+2.38 (+5.12%)

Agios Pharmaceuticals…

Agios Pharmaceuticals announced that The Lancet Oncology has published data from its global Phase 3 ClarIDHy study of TIBSOVO in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 mutation. The study met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival in patients randomized to TIBSOVO compared with placebo patients. The safety profile observed in the study was consistent with previously published data. Data from this study were previously presented at the European Society for Medical Oncology Congress, held in September 2019 in Barcelona, Spain. The ClarIDHy trial is a global, randomized Phase 3 trial in previously treated IDH1-mutant cholangiocarcinoma patients who have documented disease progression following one or two systemic therapies in the advanced setting. Patients were randomized 2:1 to receive either single-agent TIBSOVO 500 mg once daily or placebo with crossover to TIBSOVO permitted at the time of documented radiographic progression per RECIST 1.1. At the time of the primary analysis, a total of 185 patients were randomized, with 124 patients in the TIBSOVO arm and 61 patients in the placebo arm. Thirty-five patients randomized to placebo crossed over to open-label TIBSOVO upon radiographic disease progression and unblinding. Results of the study were as follows: Median PFS for patients randomized to TIBSOVO was 2.7 months compared to 1.4 months with placebo as assessed by independent radiology review. The estimated PFS rate was 32% at six months and 22% at 12 months for patients randomized to TIBSOVO, while no patients randomized to placebo were free from progression beyond six months as of the data cut-off. The most common treatment-emergent adverse events of any grade for the 121 patients who received TIBSOVO were nausea, diarrhea and fatigue. Less than third of patients experienced serious AEs in either arm. The most common Grade 3 or worse AE in both treatment groups was ascites. Patients randomized to placebo experienced a significantly greater decline in physical functioning from baseline compared to patients randomized to ivosidenib on the first day of their second 28-day treatment cycle based on European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Physical Functioning subscale scores. TIBSOVO is not approved in any country for the treatment of patients with previously treated advanced IDH1-mutant cholangiocarcinoma.

ShowHide Related Items >><<
AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

Conference/Events
Agios Pharmaceuticals participates in a conference call with JPMorgan » 11:25
05/18/20
05/18
11:25
05/18/20
11:25
AGIO

Agios Pharmaceuticals

$48.85 /

+2.41 (+5.19%)

Healthcare Analyst Rama…

Healthcare Analyst Rama holds a conference call with CEO Fouse on May 18 at 12 pm hosted by JPMorgan.

ShowHide Related Items >><<
AGIO Agios Pharmaceuticals
$48.85 /

+2.41 (+5.19%)

AGIO Agios Pharmaceuticals
$48.85 /

+2.41 (+5.19%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
AGIO Agios Pharmaceuticals
$48.85 /

+2.41 (+5.19%)

AGIO Agios Pharmaceuticals
$48.85 /

+2.41 (+5.19%)

AGIO Agios Pharmaceuticals
$48.85 /

+2.41 (+5.19%)

Conference/Events
Agios Pharmaceuticals participates in a conference call with JPMorgan » 04:55
05/18/20
05/18
04:55
05/18/20
04:55
AGIO

Agios Pharmaceuticals

$46.44 /

+1.69 (+3.78%)

Healthcare Analyst Rama…

Healthcare Analyst Rama holds a conference call with CEO Fouse on May 18 at 12 pm hosted by JPMorgan.

ShowHide Related Items >><<
AGIO Agios Pharmaceuticals
$46.44 /

+1.69 (+3.78%)

AGIO Agios Pharmaceuticals
$46.44 /

+1.69 (+3.78%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
AGIO Agios Pharmaceuticals
$46.44 /

+1.69 (+3.78%)

AGIO Agios Pharmaceuticals
$46.44 /

+1.69 (+3.78%)

AGIO Agios Pharmaceuticals
$46.44 /

+1.69 (+3.78%)

Conference/Events
Agios Pharmaceuticals participates in a conference call with JPMorgan » 15:18
05/14/20
05/14
15:18
05/14/20
15:18
AGIO

Agios Pharmaceuticals

$43.83 /

-1.75 (-3.84%)

Healthcare Analyst Rama…

Healthcare Analyst Rama holds a conference call with CEO Fouse on May 18 at 12 pm hosted by JPMorgan.

ShowHide Related Items >><<
AGIO Agios Pharmaceuticals
$43.83 /

-1.75 (-3.84%)

AGIO Agios Pharmaceuticals
$43.83 /

-1.75 (-3.84%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
AGIO Agios Pharmaceuticals
$43.83 /

-1.75 (-3.84%)

AGIO Agios Pharmaceuticals
$43.83 /

-1.75 (-3.84%)

AGIO Agios Pharmaceuticals
$43.83 /

-1.75 (-3.84%)

Hot Stocks
Agios to present updated clinical proof-of-concept data on mitapivat at EHA » 09:46
05/14/20
05/14
09:46
05/14/20
09:46
AGIO

Agios Pharmaceuticals

$45.44 /

-0.14 (-0.31%)

Agios Pharmaceuticals…

Agios Pharmaceuticals announced that mitapivat and ivosidenib clinical data will be presented at the European Hematology Association, or EHA, Annual Congress being held virtually June 11-14. The accepted abstracts are available online on the EHA meeting library website, noted the company, which also pointed out that all presentations can be accessed on demand by registered meeting attendees on the EHA Virtual Congress platform as of Friday, June 12 and will be accessible until October 15. Reference Link

ShowHide Related Items >><<
AGIO Agios Pharmaceuticals
$45.44 /

-0.14 (-0.31%)

AGIO Agios Pharmaceuticals
$45.44 /

-0.14 (-0.31%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
AGIO Agios Pharmaceuticals
$45.44 /

-0.14 (-0.31%)

AGIO Agios Pharmaceuticals
$45.44 /

-0.14 (-0.31%)

AGIO Agios Pharmaceuticals
$45.44 /

-0.14 (-0.31%)

Recommendations
Agios Pharmaceuticals should be bought now, says Piper Sandler » 05:06
05/11/20
05/11
05:06
05/11/20
05:06
AGIO

Agios Pharmaceuticals

$39.52 /

+0.27 (+0.69%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren is "even more convinced" in his Overweight rating on Agios Pharmaceuticals after hosting management for a virtual meeting. The post-earnings pullback in the shares has created an "exciting buying opportunity" ahead of the thalassemia and sickle cell data disclosures next month, and the additional, more substantial updates at year-end, Van Buren tells investors in a research note titled "Buy AGIO Now." There is little value for the PKR activation franchise in Agios shares right now, and the potential future value creation could exceed Agios's current market cap, adds the analyst, who keeps a $70 price target on the shares.

ShowHide Related Items >><<
AGIO Agios Pharmaceuticals
$39.52 /

+0.27 (+0.69%)

05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies
Conference/Events
Agios Pharmaceuticals participates in a virtual bus tour with Piper Sandler » 09:55
05/07/20
05/07
09:55
05/07/20
09:55
AGIO

Agios Pharmaceuticals

$38.70 /

+ (+0.00%)

Biotech Analyst Van Buren…

Biotech Analyst Van Buren holds a virtual bus tour with CFO Hirsch on May 7 at 10 am. Webcast Link

ShowHide Related Items >><<
AGIO Agios Pharmaceuticals
$38.70 /

+ (+0.00%)

05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies
Conference/Events
Agios Pharmaceuticals participates in a virtual bus tour with Piper Sandler » 04:55
05/07/20
05/07
04:55
05/07/20
04:55
AGIO

Agios Pharmaceuticals

$38.70 /

-0.72 (-1.83%)

Biotech Analyst Van Buren…

Biotech Analyst Van Buren holds a virtual bus tour with CFO Hirsch on May 7 at 10 am. Webcast Link

ShowHide Related Items >><<
AGIO Agios Pharmaceuticals
$38.70 /

-0.72 (-1.83%)

05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.